Open AccessEffects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor
Author(s) -
ElseMarie Bladbjerg
Publication year - 2002
Publication title -
human reproduction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.446
H-Index - 226
eISSN - 1460-2350
pISSN - 0268-1161
DOI - 10.1093/humrep/17.12.3235
Subject(s) - tissue factor pathway inhibitor , progestin , estrogen , medicine , hormone replacement therapy (female to male) , endocrinology , norethisterone , factor vii , tissue factor , ethinylestradiol , coagulation , risk factor , testosterone (patch) , population , environmental health , research methodology
Long-term hormone replacement therapy (HRT) reduces cardiovascular risk, but an early increased risk was reported in women with coronary heart disease. In such women the arterial intima can express tissue factor, and changes in coagulation factor VII (factor VII) and tissue factor pathway inhibitor (TFPI) may be deleterious.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom